Brief: Gamida Cell Says Long-Term Data From Omidubicel Phase 3 Trial Shows Certain Promising Outcomes For Patients With Blood Cancers At The Society Of Hematologic Oncology Meeting

Gamida Cell

29/09/2022 12:06

Sept 29 (Reuters) - Gamida Cell Ltd  GMDA.O :
    * LONG-TERM DATA FROM OMIDUBICEL PHASE 3 TRIAL DEMONSTRATES
OVERALL SURVIVAL AND SUSTAINABLE DURABLE OUTCOMES FOR PATIENTS
WITH BLOOD CANCERS AT THE SOCIETY OF HEMATOLOGIC ONCOLOGY
MEETING
    * GAMIDA CELL LTD - AT TEN YEARS, FOLLOW-UP DATA
DEMONSTRATED
SUSTAINED LONG-TERM BONE MARROW RECOVERY
    * GAMIDA CELL LTD - AT THREE YEARS, NEW DATA SHOWED OVERALL
SURVIVAL AND DISEASE-FREE SURVIVAL OF 63% AND 56% RESPECTIVELY
    * GAMIDA CELL LTD - LONG-TERM DATA FROM OMIDUBICEL PHASE 3
TRIAL
DEMONSTRATES OVERALL SURVIVAL AND SUSTAINABLE DURABLE OUTCOMES
    * GAMIDA CELL LTD - OMIDUBICEL PATIENTS REPORTED CLINICALLY
MEANINGFUL HEALTH-RELATED QUALITY OF LIFE SCORES COMPARED TO
UMBILICAL CORD BLOOD
    * GAMIDA CELL LTD - DATA DEMONSTRATED AN OVERALL SURVIVAL
AND
DISEASE-FREE SURVIVAL OF 63% (95% CI, 53%-73%) AND 56% (95% CI,
47%-67%) AT THREE YEARS

Source text for Eikon:  ID:nBwwRxmca 
Further company coverage:  GMDA.O 
 ((Reuters.Briefs@thomsonreuters.com;;))